A series of randomized, double-blind, placebo-controlled, crossover studies showed that six weeks of quercetin administration (162 mg/day) in overweight or obese hypertensive patients did not cause side effects such as systemic inflammation and damage to liver and kidney function, and had no significant effect on blood lipids, fasting glucose, and insulin levels, but improved ambulatory blood pressure (ABP) in a subgroup of hypertensive patients [110]; four weeks of high-dose quercetin (730 mg/day) also lowered blood pressure in patients with stage 1 hypertension [111]. This evidence concerns the gene INS and hypertensive disorder.